Compare LCTX & SWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | SWBI |
|---|---|---|
| Founded | 1990 | 1852 |
| Country | United States | United States |
| Employees | N/A | 1416 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Ordnance And Accessories |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.7M | 491.2M |
| IPO Year | N/A | N/A |
| Metric | LCTX | SWBI |
|---|---|---|
| Price | $1.71 | $10.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $4.25 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 1.2M | 506.9K |
| Earning Date | 11-06-2025 | 03-05-2026 |
| Dividend Yield | N/A | ★ 4.71% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.21 |
| Revenue | $10,816,000.00 | ★ $466,396,000.00 |
| Revenue This Year | $6.32 | $2.62 |
| Revenue Next Year | $124.49 | $3.23 |
| P/E Ratio | ★ N/A | $52.80 |
| Revenue Growth | ★ 24.05 | N/A |
| 52 Week Low | $0.37 | $7.73 |
| 52 Week High | $2.09 | $11.50 |
| Indicator | LCTX | SWBI |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 60.97 |
| Support Level | $1.64 | $10.47 |
| Resistance Level | $1.79 | $11.08 |
| Average True Range (ATR) | 0.09 | 0.26 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 51.92 | 76.33 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.